Trial Profile
Efficacy of alemtuzumab in pateints with relapsing-remitting multiple sclerosis: one year real world study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PROMiS
- 30 Oct 2018 New trial record
- 12 Oct 2018 Interim results (n=171) assessing patient reported outcomes PRO over 8 months after initiation of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.